MCID: CHR066
MIFTS: 67

Chronic Fatigue Syndrome

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 72 49 51 40 3 14 69
Myalgic Encephalomyelitis 12 72 49
Chronic Fatigue Immune Dysfunction Syndrome 49
Systemic Exertion Intolerance Disease 49
Postviral Fatigue Syndrome 12
Encephalomyelitis, Myalgic 72
Fatigue Syndrome, Chronic 41
Myalgic Encephalitis 12
Cfs 12

Classifications:



Summaries for Chronic Fatigue Syndrome

MedlinePlus : 40 Chronic fatigue syndrome (CFS) is a disorder that causes extreme fatigue. This fatigue is not the kind of tired feeling that goes away after you rest. Instead, it lasts a long time and limits your ability to do ordinary daily activities. The main symptom of CFS is severe fatigue that lasts for 6 months or more. You also have at least four of these other symptoms: Feeling unwell for more than 24 hours after physical activity Muscle pain Memory problems Headaches Pain in multiple joints Sleep problems Sore throat Tender lymph nodes CFS is hard to diagnose. There are no tests for it, and other illnesses can cause similar symptoms. Your doctor has to rule out other diseases before making a diagnosis of CFS. No one knows what causes CFS. It is most common in women in their 40s and 50s, but anyone can have it. It can last for years. There is no cure for CFS, so the goal of treatment is to improve symptoms. CFS affects people in different ways. You should work with your doctors to create a treatment program that best meets your own needs. It may include therapies to manage your symptoms, such as medicines to treat pain, sleep disorders, and other problems. It may also include coping techniques, and ways of managing your daily activities. Centers for Disease Control and Prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as myalgic encephalomyelitis, is related to chronic active epstein-barr virus infection and irritable bowel syndrome, and has symptoms including other malaise and fatigue, myalgia and muscle weakness. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Dopamine and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and brain, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

NIH Rare Diseases : 49 Chronic fatigue syndrome, also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. It generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The main symptom is disabling fatigue that does not improve with rest. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. The exact cause is not known. There is still no cure or effective treatment for this condition but there are several clinical trials. There is debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome. There is no consensus on nomenclature or classification for these disorders. Different countries, organizations, and researchers continue to use different names to describe these conditions. Last updated: 10/18/2016

CDC : 3 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may get worse after people with the illness try to do as much as they want or need to do. This symptom is known as post-exertional malaise (PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.

Wikipedia : 72 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a medical... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 330)
# Related Disease Score Top Affiliating Genes
1 chronic active epstein-barr virus infection 32.0 IL10 IL2 TGFB1
2 irritable bowel syndrome 31.9 CRH IL10 SLC6A4 TNF
3 alexithymia 30.1 COMT HTR1A SLC6A4
4 bulimia nervosa 2 29.9 COMT CRH IGF1 POMC SLC6A4
5 generalized anxiety disorder 29.9 HTR1A MAOA SLC6A4
6 lyme disease 29.9 IL1B IL6 TNF
7 personality disorder 29.7 COMT HTR1A MAOA SLC6A4 TPH2
8 arthritis 29.7 IL10 IL1B IL6 TNF
9 prostatitis 29.7 IL10 IL1B IL6 TGFB1 TNF
10 q fever 29.7 IL10 IL1B TNF
11 multiple sclerosis 29.7 IL10 IL1B IL2 IL6 TNF
12 migraine with or without aura 1 29.7 COMT HTR1A MAOA SLC6A4 TNF
13 sleep apnea 29.7 IGF1 IL6 TNF
14 juvenile rheumatoid arthritis 29.6 IL1B IL6 TNF
15 attention deficit-hyperactivity disorder 29.5 COMT HTR1A MAOA SLC6A4 TPH2
16 rheumatic disease 29.5 IL10 IL1B TNF
17 arteries, anomalies of 29.4 IL1B IL6 TNF
18 anxiety 29.4 COMT CRH HTR1A MAOA NR3C1 SLC6A4
19 body mass index quantitative trait locus 11 29.4 CRH IGF1 IL6 NR3C1 POMC TNF
20 post-traumatic stress disorder 29.4 COMT CRH IL1B MAOA NR3C1 SLC6A4
21 gastrointestinal system disease 29.3 CRH IL10 IL1B IL6 TNF
22 ulcerative colitis 29.2 IL10 IL1B IL2 IL6 TNF
23 colitis 29.2 IL10 IL1B IL2 IL6 TNF
24 rheumatoid arthritis 29.0 IL10 IL1B IL2 IL6 TGFB1 TNF
25 inflammatory bowel disease 28.4 IL10 IL1B IL2 IL6 NR3C1 TGFB1
26 major depressive disorder 27.8 COMT CRH HTR1A IL1B IL6 MAOA
27 chronic pain 11.1
28 corticosteroid-binding globulin deficiency 10.8
29 persian gulf syndrome 10.8
30 nelson syndrome 10.6 CRH NR3C1 POMC
31 acth-secreting pituitary adenoma 10.6 CRH NR3C1 POMC
32 ross river fever 10.6 COMT IL10
33 acidophil adenoma 10.6 IGF1 POMC
34 adrenal cortex disease 10.6 CRH NR3C1 POMC
35 adrenal gland disease 10.6 CRH NR3C1 POMC
36 adrenal gland hyperfunction 10.5 CRH NR3C1 POMC
37 atypical depressive disorder 10.5 CRH MAOA SLC6A4
38 sheehan syndrome 10.5 CRH IGF1 POMC
39 fasting hypoglycemia 10.5 CRH IGF1 POMC
40 acute adrenal insufficiency 10.5 IL6 POMC
41 persistent fetal circulation syndrome 10.5 CRH IGF1 POMC
42 pituitary infarct 10.5 IGF1 POMC
43 endocrine organ benign neoplasm 10.5 CRH IGF1 POMC
44 antisocial personality disorder 10.5 COMT MAOA SLC6A4
45 oral tuberculosis 10.4 IL2 TNF
46 pituitary gland disease 10.4 CRH IGF1 POMC
47 drug dependence 10.4 CRH POMC SLC6A4
48 premature ejaculation 10.4 COMT HTR1A SLC6A4
49 gonadal disease 10.4 CRH IGF1 POMC
50 eating disorder 10.4 COMT POMC SLC6A4

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


other malaise and fatigue, myalgia, muscle weakness, sciatica, pruritus, muscle spasticity, muscle rigidity, muscle cramp, (non-specific) malaise and fatigue, fever, fatigue, back pain

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TGFB1 EIF2AK2 TNF IL10 IL1B IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TGFB1 EIF2AK2 TNF IL10 IL1B IL2
3 Decreased viability with paclitaxel GR00179-A-1 9.35 IGF1 IL10 TGFB1
4 Decreased viability with paclitaxel GR00179-A-2 9.35 IGF1
5 Decreased viability with paclitaxel GR00179-A-3 9.35 TGFB1

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

43 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 IL6 IL2 HTR1A COMT CRH IL10
2 cardiovascular system MP:0005385 10.41 IL6 IL1B IL2 MAOA HTR1A COMT
3 homeostasis/metabolism MP:0005376 10.41 IL6 IL1B IL2 IL10 HTR1A COMT
4 growth/size/body region MP:0005378 10.38 IL10 IL6 IL1B IL2 IGF1 CRH
5 cellular MP:0005384 10.34 IL2 IL10 IL6 EIF2AK2 IGF1 CRH
6 hematopoietic system MP:0005397 10.34 IL6 IL1B IL2 IL10 COMT IGF1
7 endocrine/exocrine gland MP:0005379 10.33 IL6 IL2 IL10 COMT IGF1 CRH
8 immune system MP:0005387 10.31 IL2 IL10 IL6 IL1B EIF2AK2 COMT
9 mortality/aging MP:0010768 10.31 IL10 IL6 IL1B IL2 HTR1A IGF1
10 integument MP:0010771 10.29 IL6 IL1B IGF1 CRH IL10 PDCD2
11 nervous system MP:0003631 10.22 IL6 IL1B MAOA HTR1A COMT IGF1
12 adipose tissue MP:0005375 10.19 IL6 IGF1 CRH POMC NR3C1 TPH2
13 liver/biliary system MP:0005370 10.06 IL2 IL10 IL6 CRH POMC NR3C1
14 neoplasm MP:0002006 10.02 IL6 IL1B IL2 IL10 IGF1 EIF2AK2
15 muscle MP:0005369 10.01 IL10 IL6 IGF1 SLC6A4 NR3C1 SUN2
16 no phenotypic analysis MP:0003012 9.86 IL2 IL10 HTR1A CRH POMC NR3C1
17 reproductive system MP:0005389 9.81 IL2 IL10 IL6 COMT IGF1 NR3C1
18 respiratory system MP:0005388 9.65 IL6 IL2 IL10 COMT IGF1 CRH
19 skeleton MP:0005390 9.28 IL10 IL1B IL6 IGF1 CRH PDCD2

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Sodium oxybate Approved Phase 4 502-85-2 5360545
4
Iron Approved Phase 4 7439-89-6 23925
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
8
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9 tannic acid Approved, Nutraceutical Phase 4
10 Central Nervous System Depressants Phase 4
11 Adjuvants, Anesthesia Phase 4,Phase 1
12 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
13 Central Nervous System Stimulants Phase 4,Phase 2
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
16 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
17 Anesthetics Phase 4,Phase 1
18 Anesthetics, General Phase 4
19 Anesthetics, Intravenous Phase 4
20 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
21 Dopamine Agents Phase 4,Phase 2,Phase 3
22 Dopamine Uptake Inhibitors Phase 4,Phase 2
23 Ergocalciferols Phase 4
24 Bone Density Conservation Agents Phase 4
25 Sildenafil Citrate Phase 4 171599-83-0
26 Vasodilator Agents Phase 4,Phase 1
27 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
28 Phosphodiesterase 5 Inhibitors Phase 4
29 Phosphodiesterase Inhibitors Phase 4
30 Lisdexamfetamine Dimesylate Phase 4
31 Ferric Compounds Phase 4
32 Hematinics Phase 4
33 Vitamin D2 Nutraceutical Phase 4
34 Calciferol Nutraceutical Phase 4
35 Citrate Nutraceutical Phase 4
36
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
37
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
38
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 54670067 5785
39
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 1 303-98-0 5281915
40
Serotonin Phase 2, Phase 3 50-67-9 5202
41 Antidepressive Agents Phase 2, Phase 3
42 Anti-Infective Agents Phase 3,Phase 1,Phase 2
43 Immunoglobulins Phase 2, Phase 3, Phase 1
44 Protective Agents Phase 2, Phase 3,Phase 1
45 Psychotropic Drugs Phase 2, Phase 3
46 Antibodies Phase 2, Phase 3, Phase 1
47 Antioxidants Phase 2, Phase 3,Phase 1
48 Antiviral Agents Phase 3,Phase 1,Phase 2
49 Ubiquinone Phase 2, Phase 3
50 Analgesics Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 109)

# Name Status NCT ID Phase Drugs
1 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
5 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
6 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
7 Giardia Induced Fatigue and Functional Gastrointestinal Diseases Completed NCT00860236 Phase 4
8 A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
9 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
10 Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS. Unknown status NCT01907711 Phase 2, Phase 3
11 Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise Unknown status NCT01689467 Phase 2, Phase 3
12 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
13 Drug Intervention in Chronic Fatigue Syndrome Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
14 The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Completed NCT00215800 Phase 3 Ampligen
15 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
16 Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
17 Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. Completed NCT02063126 Phase 2, Phase 3
18 Exercise and Behavioral Therapy Trial (EBT). Completed NCT00007748 Phase 3
19 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3 Duloxetine 60 mg, QD
20 Ampligen in Chronic Fatigue Syndrome Active, not recruiting NCT00215813 Phase 3 Poly I: Poly C12U (Rintatolimod)
21 B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. Active, not recruiting NCT02229942 Phase 3 Rituximab;Placebo
22 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3 PG2
23 The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome Unknown status NCT01966276 Phase 2 Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
24 Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) Unknown status NCT01793415 Phase 1, Phase 2 IodoCarb (r)
25 Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) Unknown status NCT00478465 Phase 1, Phase 2 valganciclovir
26 Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Completed NCT00540254 Phase 1, Phase 2
27 Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Completed NCT01512342 Phase 2
28 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Completed NCT01156909 Phase 2 Rituximab
29 The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Completed NCT01040429 Phase 2 Clonidine;Lactose capsula
30 Acupressure for Post-Treatment Cancer Fatigue Completed NCT00959998 Phase 2
31 Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain Completed NCT00524420 Phase 2
32 Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI) Completed NCT00810368 Phase 2 Carnosine;Placebo
33 Creatine Supplementation in Chronic Fatigue Syndrome Active, not recruiting NCT02374112 Phase 2
34 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) Active, not recruiting NCT02444091 Phase 2 Cyclophosphamide
35 High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome Not yet recruiting NCT02924831 Phase 2
36 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Terminated NCT01730495 Phase 2 Etanercept
37 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Terminated NCT01156922 Phase 2 Rituximab
38 Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Terminated NCT00977171 Phase 2 Droxidopa
39 Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Withdrawn NCT01471652 Phase 2 Nutraceutical supplements;Placebo
40 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa
41 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Recruiting NCT02854683 Phase 1 Normal Saline
42 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects Recruiting NCT02955420 Phase 1 BC 007;NaCl 0.9 %
43 Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Withdrawn NCT01872351 Phase 1 Nutraceuticals
44 Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome Unknown status NCT01893619
45 Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome Unknown status NCT01534130
46 The Feasibility, Acceptability and Clinical Utility of a New Remote-mobile Technology Intervention (ASARM) for CFS/ME in a Paediatric Population Unknown status NCT02082730
47 Use of a Monitor in ME/CFS Unknown status NCT01908036
48 Genetics of Fibromyalgia Unknown status NCT00071162
49 Neuroscience Education on Osteoarthritis Unknown status NCT02246088
50 Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes Unknown status NCT01154647 citalopram;1 ml 0.9 % NaCl

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

38
Lymph Node, Testes, Brain, Pituitary, B Cells, Prostate, Amygdala

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 835)
# Title Authors Year
1
Chronic fatigue syndrome in Chinese middle-school students. ( 29369204 )
2018
2
Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. ( 29409505 )
2018
3
Rethinking childhood adversity in chronic fatigue syndrome. ( 29392095 )
2018
4
Glucocorticoid receptor DNA methylation and childhood trauma in chronic fatigue syndrome patients. ( 29275786 )
2018
5
A Molecular Neurobiological Approach to Understanding the Aetiology of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease) with Treatment Implications. ( 29411266 )
2018
6
Chronic fatigue syndrome (CFS/ME) symptom-based phenotypes and 1-year treatment outcomes in two clinical cohorts of adult patients in the UK and The Netherlands. ( 29275782 )
2018
7
Efficacy of web-based cognitive-behavioural therapy for chronic fatigue syndrome: randomised controlled trial. ( 29436329 )
2018
8
Correction: Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. ( 29420633 )
2018
9
Cerebral Blood Flow and Heart Rate Variability in Chronic Fatigue Syndrome: A Randomized Cross-Over Study. ( 29357332 )
2018
10
Value of Circulating Cytokine Profiling During Submaximal Exercise Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 29426834 )
2018
11
A reboot for chronic fatigue syndrome research. ( 29300036 )
2018
12
On chronic fatigue syndrome and nosological categories. ( 29417255 )
2018
13
Eukaryotes in the gut microbiota in myalgic encephalomyelitis/chronic fatigue syndrome. ( 29375937 )
2018
14
Improvement of severe myalgic encephalomyelitis/chronic fatigue syndrome symptoms following surgical treatment of cervical spinal stenosis. ( 29391028 )
2018
15
Cardiovascular characteristics of chronic fatigue syndrome. ( 29399336 )
2018
16
Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. ( 27727448 )
2017
17
Cognitive and behavioral coping in people with Chronic fatigue syndrome: An exploratory study searching for intervention targets for depressive symptoms. ( 28810458 )
2017
18
Chronic fatigue syndrome patients have no reason to accept the PACE trial results: Response to Keith J Petrie and John Weinman. ( 28805512 )
2017
19
Symptoms of chronic fatigue syndrome/myalgic encephalopathy are not determined by activity pacing when measured by the chronic pain coping inventory. ( 28843450 )
2017
20
Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis participants using the novel application of autoMACS magnetic separation and flow cytometry. ( 29223146 )
2017
21
Inflammation correlates with symptoms in chronic fatigue syndrome. ( 28811366 )
2017
22
Gross and fine motor function in fibromyalgia and chronic fatigue syndrome. ( 28223840 )
2017
23
Poor sleep quality is associated with greater circulating pro-inflammatory cytokines and severity and frequency of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women. ( 28038892 )
2017
24
Differentiating Multiple Sclerosis from Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. ( 29430570 )
2017
25
FITNET's Internet-Based Cognitive Behavioural Therapy Is Ineffective and May Impede Natural Recovery in Adolescents with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. A Review. ( 28800089 )
2017
26
Cognitive remediation training improves performance in patients with chronic fatigue syndrome. ( 28830024 )
2017
27
Altered right anterior insular connectivity and loss of associated functions in adolescent chronic fatigue syndrome. ( 28880891 )
2017
28
Examining clinical similarities between myalgic encephalomyelitis/chronic fatigue syndrome and D-lactic acidosis: a systematic review. ( 28592308 )
2017
29
What treatments work for anxiety in children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)? Systematic review. ( 28877941 )
2017
30
Myalgic encephalomyelitis/chronic fatigue syndrome patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys. ( 28847166 )
2017
31
Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome. ( 28129747 )
2017
32
How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies? ( 28810428 )
2017
33
Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment. ( 29284500 )
2017
34
Depression, evening salivary cortisol and inflammation in chronic fatigue syndrome: A psychoneuroendocrinological structural regression model. ( 28918107 )
2017
35
Physiological measures in participants with chronic fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise: a pilot study. ( 28782878 )
2017
36
Distress signals: Does cognitive behavioural therapy reduce or increase distress in chronic fatigue syndrome/myalgic encephalomyelitis? ( 28805513 )
2017
37
Treatment and management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: all roads lead to Rome. ( 28052319 )
2017
38
Bias, misleading information and lack of respect for alternative views have distorted perceptions of myalgic encephalomyelitis/chronic fatigue syndrome and its treatment. ( 28805527 )
2017
39
PACE trial claims for recovery in myalgic encephalomyelitis/chronic fatigue syndrome - true or false? It's time for an independent review of the methodology and results. ( 28805522 )
2017
40
Cross-Cultural Study of Information Processing Biases in Chronic Fatigue Syndrome: Comparison of Dutch and UK Chronic Fatigue Patients. ( 28836119 )
2017
41
Clinical and cost-effectiveness of the Lightning Process in addition to specialist medical care for paediatric chronic fatigue syndrome: randomised controlled trial. ( 28931531 )
2017
42
Impact of Rantes from jawbone on Chronic Fatigue Syndrome. ( 28685531 )
2017
43
Elevations of Ventricular Lactate Levels Occur in Both Chronic Fatigue Syndrome and Fibromyalgia. ( 29308330 )
2017
44
Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. ( 27998507 )
2017
45
Differential effects of childhood trauma subtypes on fatigue and physical functioning in chronic fatigue syndrome. ( 28806608 )
2017
46
Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. ( 28059425 )
2017
47
Do graded activity therapies cause harm in chronic fatigue syndrome? ( 28805516 )
2017
48
Children's experiences of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review and meta-ethnography of qualitative studies. ( 28087544 )
2017
49
Elevated brain natriuretic peptide levels in chronic fatigue syndrome associate with cardiac dysfunction: a case control study. ( 29344367 )
2017
50
Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study. ( 28302133 )
2017

Variations for Chronic Fatigue Syndrome

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.37 EIF2AK2 IL10 IL1B IL2 IL6 MAOA
2
Show member pathways
13.33 IGF1 IL10 IL1B IL2 IL6 TGFB1
3
Show member pathways
12.92 IL10 IL1B IL2 IL6 TGFB1 TNF
4
Show member pathways
12.86 EIF2AK2 IL1B IL2 IL6 RNASEL TNF
5
Show member pathways
12.75 EIF2AK2 IGF1 IL1B IL2 IL6 TGFB1
6
Show member pathways
12.66 IL10 IL1B IL2 IL6 TGFB1 TNF
7
Show member pathways
12.65 EIF2AK2 IL10 IL1B IL2 IL6 TNF
8 12.61 IL10 IL1B IL2 RNASEL TNF
9
Show member pathways
12.59 IL10 IL1B IL2 IL6 TGFB1 TNF
10
Show member pathways
12.49 IL10 IL1B IL2 IL6 TGFB1 TNF
11
Show member pathways
12.36 IL1B IL2 IL6 TNF
13 12.3 IL10 IL1B IL6 TGFB1 TNF
14
Show member pathways
12.29 IL10 IL1B TGFB1 TNF
15
Show member pathways
12.25 IGF1 IL6 TGFB1 TNF
16
Show member pathways
12.14 IGF1 IL10 IL6 TGFB1
17
Show member pathways
12.14 IL10 IL1B IL2 IL6 RNASEL TNF
18 12.12 IGF1 IL6 NR3C1 TGFB1 TNF
19 12.07 IL1B IL2 IL6 TGFB1 TNF
20 12.06 IL10 IL2 IL6 TNF
21 12.04 HTR1A MAOA SLC6A4 TPH2
22 12 IGF1 IL1B IL6 RNASEL TGFB1
23 11.98 IL1B IL6 TGFB1 TNF
24 11.95 CRH IL2 POMC TGFB1
25 11.93 IL1B IL6 TGFB1 TNF
26 11.9 IL10 IL1B IL6 TGFB1 TNF
27 11.88 IL2 IL6 NR3C1 POMC
28 11.87 IL10 IL1B IL2 TNF
29 11.84 IL10 IL1B IL6 TNF
30
Show member pathways
11.82 IL10 IL1B IL2 IL6 TGFB1 TNF
31 11.76 IL10 IL6 TGFB1 TNF
32 11.76 IL10 IL1B IL6 MAOA POMC TGFB1
33 11.69 IGF1 IL1B IL6 TGFB1 TNF
34
Show member pathways
11.67 IL1B IL2 IL6 NR3C1 TNF
35 11.63 IL1B IL6 TNF
36 11.61 IL10 IL1B IL6 TNF
37 11.6 IL10 IL1B IL2 IL6 TGFB1 TNF
38 11.59 IL2 IL6 TNF
39 11.59 IL1B IL2 TGFB1 TNF
40 11.56 IGF1 IL6 TGFB1
41 11.52 IL10 IL1B IL6 TGFB1 TNF
42 11.49 HTR1A IL10 IL1B IL6 MAOA NR3C1
43 11.46 IGF1 IL1B IL6 NR3C1 TNF
44
Show member pathways
11.42 IL10 IL2 TGFB1 TNF
45
Show member pathways
11.4 IL1B MAOA SLC6A4 TNF TPH2
46 11.39 IL10 IL1B IL6 TNF
47 11.38 IL1B IL6 TNF
48 11.38 IL10 IL1B IL6 TNF
49 11.36 IL1B IL6 TNF
50 11.28 IL10 IL1B IL2 IL6 TNF

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 CRH IGF1 IL10 IL1B IL2 IL6

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.96 IGF1 IL1B SUN2 TGFB1
2 inflammatory response GO:0006954 9.95 CRH IL10 IL1B IL6 TGFB1 TNF
3 positive regulation of cell proliferation GO:0008284 9.95 CRH HTR1A IGF1 IL1B IL2 IL6
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 IL6 TGFB1 TNF
5 cellular response to organic cyclic compound GO:0071407 9.86 IL1B TGFB1 TNF
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IGF1 IL2 IL6
7 response to estrogen GO:0043627 9.85 COMT CRH TPH2
8 positive regulation of DNA binding transcription factor activity GO:0051091 9.85 IL10 IL1B IL6 TNF
9 positive regulation of T cell proliferation GO:0042102 9.83 IL1B IL2 IL6
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 IGF1 IL6 TNF
11 positive regulation of protein phosphorylation GO:0001934 9.83 CRH IL1B IL2 TGFB1 TNF
12 negative regulation of fat cell differentiation GO:0045599 9.82 IL6 TGFB1 TNF
13 positive regulation of interleukin-6 production GO:0032755 9.81 IL1B IL6 TNF
14 response to organic substance GO:0010033 9.81 IL10 SLC6A4 TGFB1 TNF
15 positive regulation of interferon-gamma production GO:0032729 9.8 IL1B IL2 TNF
16 negative regulation of viral genome replication GO:0045071 9.79 EIF2AK2 RNASEL TNF
17 response to glucocorticoid GO:0051384 9.76 IL10 IL6 TNF TPH2
18 negative regulation of mitotic cell cycle GO:0045930 9.75 IL10 TGFB1 TNF
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.74 IL1B TGFB1 TNF
20 cellular response to dexamethasone stimulus GO:0071549 9.73 CRH NR3C1 TGFB1
21 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 EIF2AK2 IL1B IL6 TGFB1 TNF
22 positive regulation of immunoglobulin secretion GO:0051024 9.7 IL2 IL6
23 neurotransmitter catabolic process GO:0042135 9.7 COMT MAOA
24 positive regulation of gene expression GO:0010628 9.7 CRH IGF1 IL1B IL6 SLC6A4 TGFB1
25 positive regulation of regulatory T cell differentiation GO:0045591 9.69 IL2 TGFB1
26 catecholamine metabolic process GO:0006584 9.69 COMT MAOA
27 negative regulation of lipid storage GO:0010888 9.68 IL6 TNF
28 positive regulation of chemokine biosynthetic process GO:0045080 9.67 IL1B TNF
29 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
30 dopamine catabolic process GO:0042420 9.67 COMT MAOA
31 positive regulation of chemokine production GO:0032722 9.67 EIF2AK2 IL6 TNF
32 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
33 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
34 positive regulation of transcription by RNA polymerase II GO:0045944 9.65 IGF1 IL10 IL1B IL2 IL6 NR3C1
35 positive regulation of fever generation GO:0031622 9.63 IL1B TNF
36 sequestering of triglyceride GO:0030730 9.61 IL1B TNF
37 receptor biosynthetic process GO:0032800 9.6 IL10 TNF
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.59 IL1B TNF
39 positive regulation of mononuclear cell migration GO:0071677 9.58 TGFB1 TNF
40 protein kinase B signaling GO:0043491 9.56 IGF1 IL1B TGFB1 TNF
41 regulation of hematopoietic progenitor cell differentiation GO:1901532 9.54 EIF2AK2 PDCD2
42 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.54 IL10 IL1B TNF
43 regulation of serotonin secretion GO:0014062 9.52 CRH HTR1A
44 regulation of receptor activity GO:0010469 9.23 IGF1 IL10 IL1B IL2 IL6 POMC
45 immune response GO:0006955 10.1 IL10 IL1B IL2 IL6 TNF
46 positive regulation of transcription, DNA-templated GO:0045893 10.1 IGF1 IL10 IL1B IL6 TGFB1 TNF
47 negative regulation of cell proliferation GO:0008285 10.08 EIF2AK2 IL10 IL1B IL6 TGFB1
48 response to drug GO:0042493 10.01 COMT CRH IL10 SLC6A4 TGFB1

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IGF1 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.1 IL10 IL1B IL2 IL6 TGFB1 TNF

Sources for Chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....